These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 34794179

  • 1. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study.
    Lissitchkov T, Willemze A, Katragadda S, Rice K, Poloskey S, Benson C.
    Blood Adv; 2022 Feb 22; 6(4):1089-1094. PubMed ID: 34794179
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa.
    Lissitchkov T, Willemze A, Jan C, Zilberstein M, Katragadda S.
    Res Pract Thromb Haemost; 2023 May 22; 7(4):100176. PubMed ID: 37538505
    [Abstract] [Full Text] [Related]

  • 3. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII.
    Demers M, Aleman MM, Kistanova E, Peters R, Salas J, Seth Chhabra E.
    J Thromb Haemost; 2022 Jul 22; 20(7):1674-1683. PubMed ID: 35466511
    [Abstract] [Full Text] [Related]

  • 4. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
    von Drygalski A, Chowdary P, Kulkarni R, Susen S, Konkle BA, Oldenburg J, Matino D, Klamroth R, Weyand AC, Jimenez-Yuste V, Nogami K, Poloskey S, Winding B, Willemze A, Knobe K, XTEND-1 Trial Group.
    N Engl J Med; 2023 Jan 26; 388(4):310-318. PubMed ID: 36720133
    [Abstract] [Full Text] [Related]

  • 5. Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A.
    Konkle BA.
    Expert Rev Hematol; 2023 Jan 26; 16(8):567-573. PubMed ID: 37289594
    [Abstract] [Full Text] [Related]

  • 6. Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.
    Malec L, Peyvandi F, Chan AKC, Königs C, Zulfikar B, Yuan H, Simpson M, Álvarez Román MT, Carcao M, Staber JM, Dunn AL, Chou SC, d'Oiron R, Albisetti M, Demissie M, Santagostino E, Yarramaneni A, Wong N, Abad-Franch L, Gunawardena S, Fijnvandraat K, XTEND-Kids Trial Group.
    N Engl J Med; 2024 Jul 18; 391(3):235-246. PubMed ID: 39018533
    [Abstract] [Full Text] [Related]

  • 7. Efanesoctocog alfa: the renaissance of Factor VIII replacement therapy.
    Dargaud Y, Leuci A, Ruiz AR, Lacroix-Desmazes S.
    Haematologica; 2024 Aug 01; 109(8):2436-2444. PubMed ID: 38356459
    [Abstract] [Full Text] [Related]

  • 8. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
    Pipe S, Sadeghi-Khomami A, Konkle BA, Kitchen S, Negrier C, Liu M, Santagostino E, Willemze A, Abad-Franch L, Knobe K, Seth Chhabra E.
    Haemophilia; 2024 Jan 01; 30(1):214-223. PubMed ID: 37902390
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic evaluation of efanesoctocog alfa: breakthrough factor VIII therapy for hemophilia A.
    Yada K, Nogami K.
    Expert Opin Drug Metab Toxicol; 2024 Oct 04; ():1-10. PubMed ID: 39323385
    [Abstract] [Full Text] [Related]

  • 10. BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.
    Konkle BA, Shapiro AD, Quon DV, Staber JM, Kulkarni R, Ragni MV, Chhabra ES, Poloskey S, Rice K, Katragadda S, Fruebis J, Benson CC.
    N Engl J Med; 2020 Sep 10; 383(11):1018-1027. PubMed ID: 32905674
    [Abstract] [Full Text] [Related]

  • 11. Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa.
    Ryu JH, Bauer KA, Schulman S.
    J Thromb Haemost; 2023 Dec 10; 21(12):3508-3510. PubMed ID: 37734716
    [Abstract] [Full Text] [Related]

  • 12. Efanesoctocog Alfa: First Approval.
    Keam SJ.
    Drugs; 2023 May 10; 83(7):633-638. PubMed ID: 37022666
    [Abstract] [Full Text] [Related]

  • 13. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
    Seth Chhabra E, Liu T, Kulman J, Patarroyo-White S, Yang B, Lu Q, Drager D, Moore N, Liu J, Holthaus AM, Sommer JM, Ismail A, Rabinovich D, Liu Z, van der Flier A, Goodman A, Furcht C, Tie M, Carlage T, Mauldin R, Dobrowsky TM, Liu Z, Mercury O, Zhu L, Mei B, Schellenberger V, Jiang H, Pierce GF, Salas J, Peters R.
    Blood; 2020 Apr 23; 135(17):1484-1496. PubMed ID: 32078672
    [Abstract] [Full Text] [Related]

  • 14. Patient Experience With Efanesoctocog Alfa for Severe Hemophilia A: Results From the XTEND-1 Phase 3 Clinical Study Exit Interviews.
    DiBenedetti D, Neme D, Pan-Petesch B, Willemze A, Wynn T, Kragh N, Wilson A.
    Clin Ther; 2024 Dec 23; 46(12):1016-1023. PubMed ID: 39414418
    [Abstract] [Full Text] [Related]

  • 15. Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice.
    Sarafanov AG.
    Int J Mol Sci; 2023 May 11; 24(10):. PubMed ID: 37239930
    [Abstract] [Full Text] [Related]

  • 16. The von Willebrand factor-binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A.
    Ay C, Kovacevic KD, Kraemmer D, Schoergenhofer C, Gelbenegger G, Firbas C, Quehenberger P, Jilma-Stohlawetz P, Gilbert JC, Zhu S, Beliveau M, Koenig F, Iorio A, Jilma B, Derhaschnig U, Pabinger I.
    Blood; 2023 Mar 09; 141(10):1147-1158. PubMed ID: 36108308
    [Abstract] [Full Text] [Related]

  • 17. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, Pasi KJ, Hanabusa H, Pabinger I, Mahlangu J, Fogarty P, Lillicrap D, Kulke S, Potts J, Neelakantan S, Nestorov I, Li S, Dumont JA, Jiang H, Brennan A, Pierce GF.
    J Thromb Haemost; 2014 Nov 09; 12(11):1788-800. PubMed ID: 25196897
    [Abstract] [Full Text] [Related]

  • 18. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
    Solms A, Shah A, Berntorp E, Tiede A, Iorio A, Linardi C, Ahsman M, Mancuso ME, Zhivkov T, Lissitchkov T.
    Ann Hematol; 2020 Nov 09; 99(11):2689-2698. PubMed ID: 32974838
    [Abstract] [Full Text] [Related]

  • 19. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A, Moonla C, Sosothikul D.
    Haemophilia; 2023 Jan 09; 29(1):156-164. PubMed ID: 36409282
    [Abstract] [Full Text] [Related]

  • 20. Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A.
    Abdelgawad HAH, Foster R, Otto M.
    Blood Rev; 2024 Mar 09; 64():101164. PubMed ID: 38216442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.